Iniciar sesión Regístrese gratis

Acelrx Pharmaceuticals Inc Retorno sobre activos

¿Qué es el Retorno sobre activos de Acelrx Pharmaceuticals Inc?

El Retorno sobre activos de Acelrx Pharmaceuticals Inc es -74.46%

¿Cuál es la definición de Retorno sobre activos?



El rendimiento de los activos indica cuál rentables son los activos de una empresa para generar ingresos. Se calcula dividiendo la utilidad neta por el promedio de los activos totales.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Retorno sobre activos de compañías en Sector Health Care en NASDAQ en comparadas con Acelrx Pharmaceuticals Inc

¿Qué hace Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Empresas con retorno sobre activos similar a Acelrx Pharmaceuticals Inc